Peltola H, Rød T O, Jónsdóttir K, Böttiger M, Coolidge J A
Children's Hospital, University of Helsinki, Finland.
Rev Infect Dis. 1990 Jul-Aug;12(4):708-15. doi: 10.1093/clinids/12.4.708.
The five countries of Scandinavia (Denmark, Finland, Iceland, Norway, and Sweden) comprise 22.6 million inhabitants and rather homogeneous socioeconomic conditions. A survey of systemic Haemophilus influenzae diseases over the last decades revealed that the reported incidence of H. influenzae disease is increasing. In recent years, the overall incidence has been 3.5 cases per 100,000 people each year (800 cases annually); in children less than 5 years of age, the annual incidence has been 49 cases per 100,000. Meningitis represents only 52% of all systemic H. influenzae diseases, but lack of reliable data may obscure the importance of other entities. Few strains (less than 5%) are beta-lactamase-positive, and the case fatality rate is 3%. Analysis of seasonal variation shows peaks in June and September-October. If the efficacy of the H. influenzae conjugate vaccines were as high as that of a conjugate vaccine used in Finland during 1986-1987 (approximately 85% efficacy), then at least an 80% reduction in life-threatening H. influenzae infections would be achieved annually by routine immunization before or at the age of 6 months.
斯堪的纳维亚半岛的五个国家(丹麦、芬兰、冰岛、挪威和瑞典)共有2260万居民,社会经济条件较为相似。过去几十年对全身性流感嗜血杆菌疾病的一项调查显示,报告的流感嗜血杆菌疾病发病率正在上升。近年来,总体发病率为每年每10万人3.5例(每年800例);在5岁以下儿童中,年发病率为每10万人49例。脑膜炎仅占所有全身性流感嗜血杆菌疾病的52%,但缺乏可靠数据可能掩盖了其他疾病的重要性。很少有菌株(不到5%)是β-内酰胺酶阳性,病死率为3%。季节性变化分析显示,发病高峰出现在6月以及9月至10月。如果流感嗜血杆菌结合疫苗的效力与1986 - 1987年芬兰使用的一种结合疫苗的效力一样高(效力约为85%),那么通过在6个月龄之前或之时进行常规免疫接种,每年至少可使危及生命的流感嗜血杆菌感染减少80%。